Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis

C. Whalen, A. Okwera, J. Johnson, M. Vjecha, D. Hom, R. Wallis, R. Huebner, R. Mugerwa, J. Ellner

Research output: Contribution to journalArticle

Abstract

Infection with the human immunodeficiency virus (HIV) has changed both the epidemiology and natural history of tuberculosis. Despite a generally good response to effective antituberculous therapy, the prognosis remains poor. The objective of this analysis was to determine the independent predictors of survival in HIV-infected Ugandan adults with smear-positive pulmonary tuberculosis. A total of 191 HIV-infected Ugandan adults with smear-positive pulmonary tuberculosis were enrolled into a clinical trial of chemotherapy for tuberculosis. The subjects received either rifampin, isoniazid, and pyrazinamide for two months, followed by rifampin and isoniazid for six months (n = 101) or streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for eight months (n = 90). After standard measurements were made at baseline, the group was followed at regular intervals for a mean of 16 months to determine survival. During the course of follow-up, 82 (43%) of the patients died, six within the first month of therapy. The one-year survival proportion was 68% with an estimated median survival of 26 months and did not differ according to treatment regimen. The hazard for death was biphasic, high early in the course of therapy, and then again after about one year. After controlling for the treatment regimen, four independent predictors of survival were found: anergy to purified protein derivative, atypical chest roentgenogram, previous HIV- related condition, and lymphopenia. In this cohort of Ugandan adults, four simple and inexpensive predictors of survival were found. These factors suggest that the degree of immunosuppression was a major determinant of survival.

Original languageEnglish (US)
Pages (from-to)1977-1981
Number of pages5
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume153
Issue number6 I
StatePublished - 1996
Externally publishedYes

Fingerprint

Pulmonary Tuberculosis
HIV
Isoniazid
Survival
Thioacetazone
Rifampin
Tuberculosis
Therapeutics
Pyrazinamide
Lymphopenia
Streptomycin
Immunosuppression
Epidemiology
Thorax
Clinical Trials
Drug Therapy
Infection
Proteins

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Whalen, C., Okwera, A., Johnson, J., Vjecha, M., Hom, D., Wallis, R., ... Ellner, J. (1996). Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine, 153(6 I), 1977-1981.

Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. / Whalen, C.; Okwera, A.; Johnson, J.; Vjecha, M.; Hom, D.; Wallis, R.; Huebner, R.; Mugerwa, R.; Ellner, J.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 153, No. 6 I, 1996, p. 1977-1981.

Research output: Contribution to journalArticle

Whalen, C, Okwera, A, Johnson, J, Vjecha, M, Hom, D, Wallis, R, Huebner, R, Mugerwa, R & Ellner, J 1996, 'Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis', American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 6 I, pp. 1977-1981.
Whalen, C. ; Okwera, A. ; Johnson, J. ; Vjecha, M. ; Hom, D. ; Wallis, R. ; Huebner, R. ; Mugerwa, R. ; Ellner, J. / Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. In: American Journal of Respiratory and Critical Care Medicine. 1996 ; Vol. 153, No. 6 I. pp. 1977-1981.
@article{85cfd9837aaf457ebdd6e748927e9269,
title = "Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis",
abstract = "Infection with the human immunodeficiency virus (HIV) has changed both the epidemiology and natural history of tuberculosis. Despite a generally good response to effective antituberculous therapy, the prognosis remains poor. The objective of this analysis was to determine the independent predictors of survival in HIV-infected Ugandan adults with smear-positive pulmonary tuberculosis. A total of 191 HIV-infected Ugandan adults with smear-positive pulmonary tuberculosis were enrolled into a clinical trial of chemotherapy for tuberculosis. The subjects received either rifampin, isoniazid, and pyrazinamide for two months, followed by rifampin and isoniazid for six months (n = 101) or streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for eight months (n = 90). After standard measurements were made at baseline, the group was followed at regular intervals for a mean of 16 months to determine survival. During the course of follow-up, 82 (43{\%}) of the patients died, six within the first month of therapy. The one-year survival proportion was 68{\%} with an estimated median survival of 26 months and did not differ according to treatment regimen. The hazard for death was biphasic, high early in the course of therapy, and then again after about one year. After controlling for the treatment regimen, four independent predictors of survival were found: anergy to purified protein derivative, atypical chest roentgenogram, previous HIV- related condition, and lymphopenia. In this cohort of Ugandan adults, four simple and inexpensive predictors of survival were found. These factors suggest that the degree of immunosuppression was a major determinant of survival.",
author = "C. Whalen and A. Okwera and J. Johnson and M. Vjecha and D. Hom and R. Wallis and R. Huebner and R. Mugerwa and J. Ellner",
year = "1996",
language = "English (US)",
volume = "153",
pages = "1977--1981",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6 I",

}

TY - JOUR

T1 - Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis

AU - Whalen, C.

AU - Okwera, A.

AU - Johnson, J.

AU - Vjecha, M.

AU - Hom, D.

AU - Wallis, R.

AU - Huebner, R.

AU - Mugerwa, R.

AU - Ellner, J.

PY - 1996

Y1 - 1996

N2 - Infection with the human immunodeficiency virus (HIV) has changed both the epidemiology and natural history of tuberculosis. Despite a generally good response to effective antituberculous therapy, the prognosis remains poor. The objective of this analysis was to determine the independent predictors of survival in HIV-infected Ugandan adults with smear-positive pulmonary tuberculosis. A total of 191 HIV-infected Ugandan adults with smear-positive pulmonary tuberculosis were enrolled into a clinical trial of chemotherapy for tuberculosis. The subjects received either rifampin, isoniazid, and pyrazinamide for two months, followed by rifampin and isoniazid for six months (n = 101) or streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for eight months (n = 90). After standard measurements were made at baseline, the group was followed at regular intervals for a mean of 16 months to determine survival. During the course of follow-up, 82 (43%) of the patients died, six within the first month of therapy. The one-year survival proportion was 68% with an estimated median survival of 26 months and did not differ according to treatment regimen. The hazard for death was biphasic, high early in the course of therapy, and then again after about one year. After controlling for the treatment regimen, four independent predictors of survival were found: anergy to purified protein derivative, atypical chest roentgenogram, previous HIV- related condition, and lymphopenia. In this cohort of Ugandan adults, four simple and inexpensive predictors of survival were found. These factors suggest that the degree of immunosuppression was a major determinant of survival.

AB - Infection with the human immunodeficiency virus (HIV) has changed both the epidemiology and natural history of tuberculosis. Despite a generally good response to effective antituberculous therapy, the prognosis remains poor. The objective of this analysis was to determine the independent predictors of survival in HIV-infected Ugandan adults with smear-positive pulmonary tuberculosis. A total of 191 HIV-infected Ugandan adults with smear-positive pulmonary tuberculosis were enrolled into a clinical trial of chemotherapy for tuberculosis. The subjects received either rifampin, isoniazid, and pyrazinamide for two months, followed by rifampin and isoniazid for six months (n = 101) or streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for eight months (n = 90). After standard measurements were made at baseline, the group was followed at regular intervals for a mean of 16 months to determine survival. During the course of follow-up, 82 (43%) of the patients died, six within the first month of therapy. The one-year survival proportion was 68% with an estimated median survival of 26 months and did not differ according to treatment regimen. The hazard for death was biphasic, high early in the course of therapy, and then again after about one year. After controlling for the treatment regimen, four independent predictors of survival were found: anergy to purified protein derivative, atypical chest roentgenogram, previous HIV- related condition, and lymphopenia. In this cohort of Ugandan adults, four simple and inexpensive predictors of survival were found. These factors suggest that the degree of immunosuppression was a major determinant of survival.

UR - http://www.scopus.com/inward/record.url?scp=0030014233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030014233&partnerID=8YFLogxK

M3 - Article

VL - 153

SP - 1977

EP - 1981

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6 I

ER -